Shanghai - Delayed Quote CNY

North China Pharmaceutical Company.Ltd (600812.SS)

Compare
6.29
+0.04
+(0.64%)
At close: 3:00:01 PM GMT+8
Loading Chart for 600812.SS
  • Previous Close 6.25
  • Open 6.20
  • Bid 6.29 x --
  • Ask 6.30 x --
  • Day's Range 6.19 - 6.50
  • 52 Week Range 4.03 - 6.91
  • Volume 30,141,300
  • Avg. Volume 35,494,731
  • Market Cap (intraday) 10.792B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 89.86
  • EPS (TTM) 0.07
  • Earnings Date --
  • Forward Dividend & Yield 0.01 (0.16%)
  • Ex-Dividend Date Jul 18, 2024
  • 1y Target Est --

North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China. The company primarily offers anti-infective drugs; biotechnology drugs; cardiovascular cerebrovascular; immunomodulators; and vitamins and health products. It also provides chemical pharmaceuticals, biological agricultural and veterinary drugs. North China Pharmaceutical Company.Ltd was founded in 1992 and is based in Shijiazhuang, China.

www.ncpc.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600812.SS

View More

Performance Overview: 600812.SS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600812.SS
21.66%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

600812.SS
31.61%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

600812.SS
18.00%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

600812.SS
18.97%
SSE Composite Index (000001.SS)
20.91%

Compare To: 600812.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600812.SS

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    10.72B

  • Enterprise Value

    20.51B

  • Trailing P/E

    84.46

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.09

  • Price/Book (mrq)

    1.99

  • Enterprise Value/Revenue

    2.08

  • Enterprise Value/EBITDA

    12.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.29%

  • Return on Assets (ttm)

    2.15%

  • Return on Equity (ttm)

    3.32%

  • Revenue (ttm)

    9.87B

  • Net Income Avi to Common (ttm)

    126.99M

  • Diluted EPS (ttm)

    0.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.66B

  • Total Debt/Equity (mrq)

    171.54%

  • Levered Free Cash Flow (ttm)

    710.74M

Research Analysis: 600812.SS

View More

Company Insights: 600812.SS

Research Reports: 600812.SS

View More

People Also Watch